SPECTA

Advances in our molecular understanding of cancer mean we can selectively target specific patient profiles, leading to precision treatments in oncology. However, conducting clinical trials for sometimes rare subsets of patients can be logistically and technically challenging.

SPECTA (Screening cancer Patients for Efficient Clinical Trial Access) is a collaborative European platform that helps deliver high-quality, translational research across tumor types and molecular alterations.

The platform provides an integrated and shared mechanism, with rapid access to patient data and biological samples to enable the quick implementation of new clinical trials and robust translational research. It provides access to state-of-the-art technical services for biobanking and molecular profiling, ensuring research is efficient, reproducible, traceable, and high-quality.

Member area

For SPECTA, please enroll patients with the tumor type specified in the table, ONLY when the status is green. You can enroll those patients by clicking on the , next to the green status. Please note that your electronic database password is required for access.

For any questions, please contact the general SPECTA e-mail address: specta@eortc.be.

 

Tumor type Projects Status
Advanced Anal Carcinoma RP-1610 – Epidemiologic study Open
Advanced Biliary Tract Carcinoma
(intrahepatic, perihilar and distal bile ducts)
RP-1610 – Epidemiologic study Open
Advanced Neuroendocrine Tumors
(well- and moderately-differentiated, including Carcinoid)
RP-1610 – Epidemiologic study Open
Advanced Uterine Carcinoma RP-1610 – Epidemiologic study Open
Advanced Carcinoma of Cervix Uteri RP-1610 – Epidemiologic study Open
Advanced Carcinoma of the Vulva RP-1610 – Epidemiologic study Open
Advanced Thyroid Carcinoma RP-1610 – Epidemiologic study Open
Advanced Salivary Gland Carcinoma RP-1610 – Epidemiologic study Open
Advanced Small Cell Lung Carcinoma RP-1610 – Epidemiologic study To be opened
Advanced Malignant Pleural Mesothelioma RP-1610 – Epidemiologic study To be opened
Non Small Cell Lung Carcinoma Lung Cancer Personalized Medicine To be opened
High Grade Diffuse Astrocytic and Oligodendroglial Tumors
12-29 years old ONLY
RP-1759 – AYA/TYA To be opened
High Grade other Astrocytic Tumors
12-29 years old ONLY
RP-1759 – AYA/TYA To be opened
Non-Grade 1 Bone Sarcoma
12-29 years old ONLY
RP-1759 – AYA/TYA To be opened
Non-Grade 1 Soft Tissue Sarcoma
12-29 years old ONLY
RP-1759 – AYA/TYA To be opened
Adenocarcinoma and Squamous
Carcinoma of the Colon and Rectum
CRC Personalized Medicine To be opened

Projects description

RP-1610 -Epidemiologic study

Advanced:
Anal Carcinoma, Biliary Tract Carcinoma (intrahepatic, perihilar and distal bile ducts), Neuroendocrine Tumors (well- and moderately-differentiated, including Carcinoid), Uterine Carcinoma, Carcinoma of Cervix Uteri, Carcinoma of the Vulva, Small Cell Lung Carcinoma, Malignant Pleural Mesothelioma, Thyroid Carcinoma, Salivary Gland Carcinoma patients.

For this study, FFPE tissue (block mandatory) and blood will be collected at study entry. To note, we are also enrolling retrospective patients. This epidemiological study will study the relationship between biomarker status (PD-L1, MSI and a Gene Expression Profile – GEP) and OS and PFS in this patient population treated with standard of care.

Lung Cancer Personalized Medicine

Non Small Cell Lung Carcinoma patients

For this study, FFPE tissue will be collected at diagnosis, and used for NGS sequencing. After molecular tumor board validation, you will be informed if your patient is eligible for a specific targeted trial, such as:

  • phase 2 STARTRK-2 clinical trial with Entrectinib (Ignyta trial) for patients with NTRK1/2/3, ROS1 or ALK gene rearrangements
  • Phase 1 clinical trial with LOXO-292 for patients with RET-Fusion Lung Cancer

Blood will be collected at diagnosis and follow-up, and used as liquid biopsy to support the European funded project called Cancer-ID. The goal of this project is to develop/improve and standardize methods for liquid biopsy collection and analysis.

RP-1759 – AYA/TYA

12-29 year-old: Non-Grade 1 Bone and Soft Tissue Sarcoma (including Synovial Sarcoma), High Grade Diffuse Astrocytic and Oligodendroglial Tumors and other High Grade Astrocytic Tumors patients

EORTC wants to develop a sequencing project targeting specifically young adults (12 to 29 years old) with rare cancer:

  • to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease
  • to improve the inclusion of young adults into clinical trials.

The pilot study will be focusing on young adults with high grade glioma as well as non-grade 1 bone and soft tissue sarcoma. The aim of the pilot phase is to test the infrastructure and our accrual potential in this age group of patients.

For this project, we will collect FFPE tissue at study entry to perform NGS sequencing and also implement a central pathology review as well as a molecular tumor board, to bring the clinical knowledge back to the patient and the clinician.

CRC Personalized Medicine

Adenocarcinoma and Squamous Carcinoma of the Colon and Rectum patients

For this study, FFPE tissue will be collected at study entry, and used to assess eligibility for the STARTRK-2 clinical trial (Ignyta phase 2 trial for Entrectinib). You will then be informed if your patient is eligible for this trial.